ViperaTAb™ for European common adder envenomation
ViperaTAb™ is a venom antidote product for treatment of snakebites from the European common adder (Vipera berus). This product is currently being sold on a named patient basis in Scandinavia under an agreement with Swedish Orphan International AB and in the rest of Europe by Protherics. We estimate that the ViperaTAb™ market has the potential to be worth up to €5 million in Europe.
PRODUCT SUPPLY DETAILS